Présentation de l'entreprise
Lumexa Imaging Holdings, Inc. owns and operates a network of diagnostic imaging centres across the United States, delivering a comprehensive suite of outpatient medical services. The company's core business encompasses advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), alongside traditional X-ray and ultrasound technologies. Operating within the broader healthcare sector and specifically the medical devices industry, the firm provides essential diagnostic infrastructure that supports clinical decision-making for physicians and patients. With a market capitalization of $914.97 million and annual revenue of $1.02 billion, the company demonstrates significant scale in a specialized service sector. The employee count stands at 4,064, indicating a substantial operational footprint that requires extensive management and logistical coordination. These valuation and revenue figures suggest that Lumexa Imaging Holdings, Inc. holds a considerable position as a mid-to-large-cap entity within the medical imaging landscape, capable of influencing regional market dynamics through its service delivery capabilities.
Santé financière
The company reported trailing twelve-month revenue of $1.02 billion, yet recorded a net income of -$47,104,000, highlighting a substantial gap between top-line generation and bottom-line profitability. This negative net income relative to the revenue scale reveals a cost structure where operating expenses, including cost of goods sold and administrative overhead, significantly erode gross profits before reaching the net income line. Despite the net loss, the entity generated an EBITDA of $91.96 million, suggesting that while accounting for non-cash items and interest, the core operating cash generation remains positive. The free cash flow stands at $17.88 million, which provides the company with essential financial flexibility to fund capital expenditures for imaging equipment upgrades without relying immediately on external financing. Analyzing the margins shows a gross margin of 15.4%, an operating margin of 1.7%, and a profit margin of -4.6%, indicating that the company operates with thin gross profitability and currently incurs losses after all operating and non-operating expenses. The balance sheet presents a leveraged profile with total debt of $962.50 million against cash reserves of $58.83 million, resulting in a debt-to-equity ratio of 164.22. This high leverage level implies that the company relies heavily on debt financing to support its asset base and operational expansion. Liquidity management is assessed via a current ratio of 1.27, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, though the buffer is relatively narrow. Return on equity is -12.6% and return on assets is 1.9%, metrics that reveal management is currently unable to generate positive shareholder returns and faces challenges in optimizing asset efficiency relative to the capital invested.
Évaluation de la valorisation
Valuation metrics present a complex picture with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is 9.45. The disparity between a non-existent trailing multiple and a low forward P/E implies that the market expects earnings to turn positive or improve significantly in the coming fiscal period to justify the current stock price. The price-to-book ratio is 1.56, indicating that the market values the company at a premium of 56% over its net asset book value, which often reflects intangible assets like the brand and patient base not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 0.89 and an EV/EBITDA of 19.78, suggesting the stock trades at less than one dollar of sales per dollar of revenue, yet commands a significant multiple on enterprise value relative to earnings before interest, taxes, depreciation, and amortization. The 52-week trading range spans from a low of $7.23 to a high of $19.45, meaning the current price sits somewhere within this band, reflecting market sentiment regarding its turnaround potential. The beta value is listed as N/A, which precludes a direct comparison of price volatility relative to the broader market index based on historical standard deviation data provided.
Growth & Income
Revenue growth over the last year stands at 7.9%, while earnings growth is listed as N/A due to the reported net loss in the trailing twelve months. The divergence between positive revenue growth and the absence of earnings growth implies that top-line expansion is currently being consumed by expenses rather than translating into immediate profit. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating a strategy of retaining all earnings to fund operations, debt reduction, or capital investment rather than distributing cash to shareholders. This reinvestment approach is typical for growth-stage companies or those undergoing a profitability transition, prioritizing internal capital generation over external income distribution. The overall growth and income profile is characterized by robust revenue expansion coupled with a lack of current profitability and dividend distribution, positioning the company as a pure play on operational improvement and market share consolidation within the diagnostic imaging sector.